Vaginal candidiasis
Also known as Thrush
Vaginal candidiasis is a symptomatic inflammation of the vagina and/or vulva caused by a superficial fungal infection (usually yeasts of the genus Candida), and most commonly occurs in women of reproductive age.
Article by Margaret Perry
Expand all
Collapse all
Definition
Vaginal candidiasis or vulvovaginal candidiasis, more commonly known as thrush, is an unpleasant condition that affects women. Vaginal candidiasis is a symptomatic inflammation of the vagina and/or vulva caused by a superficial fungal infection (usually yeasts of the genus Candida), and most commonly occurs in women of reproductive age (National Institute for Health and Care Excellence (NICE), 2023a).
The condition is generally classified as:
- Acute vaginal candidiasis: a first or single isolated presentation
- Recurrent vaginal candidiasis: at least four episodes during a 12-month period, with at least two episodes confirmed by microscopy or culture, when the patient is symptomatic (Saxon et al, 2019)
To view the rest of this content login below; or read sample articles.
Symptoms
Symptoms of vaginal candidiasis are very common, with estimates suggesting that approximately 75% of women will have at least one episode in their lifetime, and 40–45% of women will have two or more episodes (Centers for Disease Control and Prevention, 2022). True prevalence rates are difficult to confirm, because many women may self-treat the condition with over-the-counter medications. Presentation frequently differs and varies in severity (from mild to severe). The most common symptoms of vaginal candidiasis include:
- vaginal soreness and itching
- vaginal discharge – this is usually thick and white in colour and has an appearance which resembles cottage cheese and is typically not odorous
- the vaginal area is very red (erythematous) on examination
- the skin around the vaginal and vulval areas can be cracked and inflamed
- intercourse may be uncomfortable or painful
- in some cases, the infection can be more severe and the area of redness may extend to
To view the rest of this content login below; or read sample articles.
Aetiology
In healthy adult women, during the reproductive years, the vaginal flora is a host to many microorganisms, including Candida, which do not usually cause any problems unless there are changes to the environment. Overgrowth of the causative organism leads to vaginal infection.
Lactobacillus is the most frequently isolated organism from the vagina of healthy women, and its role is to maintain an acidic pH, with the production of substances which keep the vagina healthy and prevent the development of infection by Candida or any other pathogenic organisms (Chen et al, 2021). Lactobacillus spp. normally flourishes in the vaginal anaerobic environment and produces various antimicrobial compounds, such as lactic acid, hydrogen peroxide (H2O2) and bacteriocins. These contribute to a healthy vaginal microbiome and establish a defence against invading pathogens (Chen et al, 2021).
Minimal disturbance to the healthy environment is needed for Candida organisms to become pathogenic and cause the
To view the rest of this content login below; or read sample articles.
Diagnosis
Diagnosis can often be made on history and clinical examination. Investigations are not routinely needed for women presenting with typical symptoms, but a high vaginal swab can be undertaken if the diagnosis is uncertain or the patient’s symptoms are resistant to treatment or recurrent (NICE, 2023a). When clinical examination is not possible, a self-collected vaginal swab for microscopy and culture is an acceptable alternative to samples taken by clinicians (Barnes et al, 2017).
To view the rest of this content login below; or read sample articles.
Treatment
Treatment usually involves both oral and topical medications, with a clinical and mycological cure rate of over 80% (Saxon et al, 2019). Please refer to the most up-to-date guidance for specific prescription and dosage recommendations.
Non-pregnant women
Fluconazole is recommended, but if oral treatment is contraindicated, clotrimazole pessary can be prescribed.
Alternative prescriptions include:
- clotrimazole vaginal cream (10%) intravaginally
- clotrimazole pessary intravaginally
- econazole pessary intravaginally
- fenticonazole capsule intravaginally
- miconazole capsule intravaginally
- miconazole vaginal cream (2%) intravaginally
- itraconazole orally (Saxon et al, 2019; NICE, 2023b)
Oral treatment can cause adverse effects in some women, so patients should be given a choice between oral or vaginal treatments. Clinicians should refer to NICE guidelines for contraindications, adverse effects and drug interactions before prescribing (NICE, 2023b).
Pregnancy and breastfeeding
Oral treatments are unsuitable for use during pregnancy or if there is a risk of pregnancy, or for women who are
To view the rest of this content login below; or read sample articles.
NMC proficiencies
Nursing and Midwifery Council: standards of proficiency for registered nurses
Part 1: Procedures for assessing people’s needs for person-centred care
1. Use evidence-based, best practice approaches to take a history, observe, recognise and accurately assess people of all ages
Part 2: Procedures for the planning, provision and management of person-centred nursing care
11.1 carry out initial and continued assessments of people receiving care and their ability to self-administer their own medications
11.2 recognise the various procedural routes under which medicines can be prescribed, supplied, dispensed, and administered; and the laws, policies, regulations, and guidance that underpin the
To view the rest of this content login below; or read sample articles.
Resources
Barnes P, Vieira R, Harwood J, Chauhan M. Self-taken vaginal swabs versus clinician-taken for detection of candida and bacterial vaginosis: a case-control study in primary care. Br J Gen Pract. 2017;67(665):e824-e829. https://doi.org/10.3399/bjgp17X693629
Centers for Disease Control and Prevention. Vaginal candidiasis. 2022. https://www.cdc.gov/fungal/diseases/candidiasis/genital/index.html (accessed 31 January 2024)
Chaplin S. SGLT2 inhibitors and risk of genitourinary infections. Prescriber. 2016;27:26-23. https://doi.org/10.1002/psb.1521
Chen X, Lu Y, Chen T, Li R. The female vaginal microbiome in health and bacterial vaginosis. Front Cell Infect Microbiol. 2021;11:631972. https://doi.org/10.3389/fcimb.2021.631972
Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339-e347. https://doi.org/10.1016/S1473-3099(18)30103-8
Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida infection: an emerging threat. Interdiscip Perspect Infect Dis. 2014;2014:615958. https://doi.org/10.1155/2014/615958
Fitzgerald G. Vulvovaginal candidiasis. 2017. https://teachmeobgyn.com/sexual-health/non-transmitted-infections/vulvovaginal-candidiasis/ (accessed 31 January 2024)
Jeanmonod R, Chippa V, Jeanmonod D. Vaginal candidiasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023
Lazaro N. Sexually transmitted infections in primary care. 2013.
To view the rest of this content login below; or read sample articles.